Clinical Trial Update: A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/Phase 2 clinical trial testing lorlatinib in combination with ramucirumab in people with non-small cell lung cancer. The study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Lorbrena (lorlatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non Small Cell Lung Cancer, Metastatic | Phase 1, Phase 2 | Status: RECRUITING